Pallas Health vs CoreAgeRx: clinician options vs flat monthly price

Quick verdict: Pallas Health vs CoreAgeRx

Pallas Health and CoreAgeRx both offer clinician-reviewed online GLP-1 programs, but they differ clearly: Pallas emphasizes clinician selection between FDA-approved brand pens and US-compounded semaglutide or tirzepatide with an all-in plan price, while CoreAgeRx emphasizes flat monthly pricing with no membership fee and a consistent per-month charge. Early verdict: choose Pallas if you want a clinician to pick brand-name or a compounded option inside a single intake; choose CoreAgeRx if you prioritize predictable same-price-every-month billing.

See Pallas clinician-selected plans

How they compare at a glance

Criteria	Pallas Health	CoreAgeRx
Treatment options	FDA-approved Wegovy, Ozempic, Zepbound, Mounjaro, or compounded semaglutide/tirzepatide chosen by a US-licensed clinician	Semaglutide and tirzepatide options with dose limits noted; treatment available when a licensed clinician determines it is medically appropriate
Pricing model	Compounded semaglutide $139 first month then $597 per 12 weeks (about $199/mo avg); compounded tirzepatide $179 first month then $897 per 12 weeks ($299/mo avg); brand-name cash-pay monthly prices listed	Flat monthly pricing promoted: tirzepatide $129/mo, semaglutide $79/mo; “Same Price. Every Month.”
Membership & fees	No membership fee; one all-in plan price includes provider care, check-ins and messaging	No membership fee; messaging of no hidden fees or membership required
Delivery & compounding	Compounded in the USA by licensed compounding pharmacies; free expedited shipping reported	Details on shipping and pharmacy not fully published on captured landing page; regulatory note that approval status must be confirmed
Regulatory note	Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality	Compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality

Distinctive difference 1: Clinician choice of brand vs compounded

Pallas Health presents both routes from one intake: a US-licensed clinician reviews your health history and can choose either an FDA-approved brand-name pen or a per-patient compounded semaglutide or tirzepatide prepared in the USA when a brand medication is not the right fit. CoreAgeRx emphasizes available semaglutide and tirzepatide dosing but the captured evidence focuses on price consistency rather than an explicit same-intake choice between brand and compounded products.

Distinctive difference 2: Pricing structure and predictability

Pallas lists an introductory first-month price and renewal cadence for compounded plans: semaglutide $139 first month then $597 every 12 weeks (about $199/mo avg); tirzepatide $179 first month then $897 every 12 weeks ($299/mo avg). Brand-name options at Pallas are shown as cash-pay monthly figures. CoreAgeRx markets a flat monthly price and stresses “Same Price. Every Month.” with tirzepatide at $129/month and semaglutide at $79/month on the captured page.

View CoreAgeRx flat monthly pricing

Distinctive difference 3: Billing, membership and plan inclusions

Pallas advertises one all-in plan price that includes clinician review, ongoing check-ins and care-team messaging with no membership fee and a self-serve portal. CoreAgeRx highlights no membership fee and no billing surprises with an emphasis that price will not increase month to month. The specific inclusions and renewal terms for CoreAgeRx were not fully published on the captured landing page and should be confirmed before enrollment.

Distinctive difference 4: State requirements and visit type

Pallas notes it is 100% online and asynchronous in most states, with a video visit required in seven states plus Washington, D.C. CoreAgeRx promotes a short 3-minute online visit on the captured page; captured evidence also warns that treatment is available only when a licensed clinician determines it is medically appropriate.

Other practical notes from the sources

Both providers require clinician eligibility determination. Pallas states it does not bill insurance and that cash-pay is required; FSA/HSA use may require a Letter of Medical Necessity. CoreAgeRx also states no insurance requirement for the visit but captured landing-page details on insurance handling, pharmacy partner and renewal terms were not published or could not be verified on the captured page.

Compare Pallas plan details and clinician options

Short comparison summary

In the Pallas Health vs CoreAgeRx comparison, Pallas centers on clinician-selected brand or US-compounded options with specific first-month and renewal pricing for compounded plans, included provider care and asynchronous intake in most states. CoreAgeRx centers on a predictable flat monthly price and emphasizes no membership fee and same-price-every-month messaging. Regulatory and eligibility notes apply to both.

Check CoreAgeRx enrollment and price lock

Choose Pallas if…

• You want a US-licensed clinician to decide between FDA-approved brand-name pens and a per-patient compounded semaglutide or tirzepatide option during one intake
• You prefer an all-in plan price that explicitly includes provider care, check-ins and messaging and do not want insurance billing
• You accept that compounded medications are not FDA-approved and that Pallas uses US compounding pharmacies

Choose CoreAgeRx if…

• You prioritize a flat monthly price and messaging of “Same Price. Every Month.” for semaglutide or tirzepatide and want predictable month-to-month billing
• You prefer the option described on the captured landing page of a short online visit and want to confirm eligibility, pharmacy and renewal terms before enrolling